All News
Pain Relief in RA: JAK Better than TNF Inhibitors?
Targeted drugs for rheumatoid arthritis (RA) are not created equal when it comes to pain relief, a retrospective study from Sweden indicated, although the differences appeared to be modest.
https://t.co/olXQMGm2h8 https://t.co/Em7ydT33Ui
Dr. John Cush RheumNow ( View Tweet)
Blue Collar Arthritis (10.25.2024)
Dr. Jack Cush reviews the news and journal articles from this past week on RheumNow.com.
Read Article
2 yr results from the PRAIRI study - 78 at-risk (for RA) pts Rx w/ placebo or 1000 mg IV RTX + I00 mg methylprednisolone (MP). While 1 yr result showed brief delay in RA development, at 2 yrs there was no benefit for QOL or RA development https://t.co/1CzEQn5zL4 https://t.co/Wvr2kWvDC5
Links:
Dr. John Cush RheumNow ( View Tweet)
Pain Relief in RA: JAK Better than TNF Inhibitors?
Targeted drugs for rheumatoid arthritis (RA) are not created equal when it comes to pain relief, a retrospective study from Sweden indicated, although the differences appeared to be modest.
https://t.co/XjJtfIu0Ku https://t.co/xOVernmgHE
Dr. John Cush RheumNow ( View Tweet)
RBC mitochondrial DNA triggers type I interferon (IFN) production in macrophages leading to production of interleukin-1β and inflammasome activation - Making IFN & IL-1B monocytes another potential therapeutic target in #SLE https://t.co/za878eodKS https://t.co/NomRDJTm0u https://t.co/nLB189HeNi
Dr. John Cush RheumNow ( View Tweet)
RBC mitochondrial DNA triggers type I interferon (IFN) production in macrophages leading to production of interleukin-1β and inflammasome activation - Making IFN & IL-1B monocytes another potential therapeutic target in #SLE https://t.co/za878eodKS https://t.co/NomRDJTm0u https://t.co/nLB189HeNi
Dr. John Cush RheumNow ( View Tweet)
Biologic (bio-originators) & biosimilar serious Infx rates are low & similar. Retro Study w/ 2+ yrs F/U shows hosp. Infx to be 7% infliximab & 2% etanercept. Similar SIE w/ ETA IR = 11.8 (7.9, 16.8) vs 8.4 (6.9, 10.1) & INFLX SIE IR= 33.4 (27.2, 40.1) vs 29.3 (26.6,… https://t.co/i2rP88ofEP https://t.co/XBW4tLC8YH
Dr. John Cush RheumNow ( View Tweet)
Metanalysis of 40 papers, 486,465 RA pts & 3,928 incident ILD outcomes shows no signif risk of ILD w/ DMARD use; no ILD risk w/ TOFA or TNFi (Oral Surveillance n=2,911; OR 0.94). MTX use yielded a Lower ILD risk (OR 0.49; 0.32 to 0.76) vs no MTX use. https://t.co/Es8yyEiD8r https://t.co/qOYPkWNi9o
Links:
Dr. John Cush RheumNow ( View Tweet)
Early bird registration for RheumNow Live is now open! Join us Feb 8-9 in Dallas, TX.
Join the Revolution in Rheumatology Education!
https://t.co/ygjZRMVkOZ
Links:
Dr. John Cush RheumNow ( View Tweet)
World renowned faculty delivering state of the art lectures. Early bird registration for RheumNow Live is now open!
https://t.co/Yk8dKDdZie https://t.co/d14Mq2AxlI
Links:
Dr. John Cush RheumNow ( View Tweet)
Korean Claims analysis of 413 radiographic axial spondyloarthritis (TNFi exposed=75 ). Recurrent CV events = 32 per 1,000 person-years; but lower if TNFi Rx'd = 19/1000PYs. TNFi exposure significantly lowered risk of recurrent CV events https://t.co/f69SHpXZCx https://t.co/ofpg0JbrR1
Dr. John Cush RheumNow ( View Tweet)
Have a a rheumatology question or case for Jack Cush? Record it here and we may feature it on an upcoming podcast. Tell us your name and where you practice rheumatology.
https://t.co/wvZYVbVW83 https://t.co/n26xAeU64s
Dr. John Cush RheumNow ( View Tweet)
CORRECTION!! UCB announced the LAUNCH of a new phase 3b BE BOLD trial - this study has no report results as yet. It WILL BE a H2H RCTcomparing bimekizumab & rizankizumab in adult #PsA pts using an ACR50 primary endpoint. Yesterday we incorrectly reported this as a completed… https://t.co/apa6VMuQTi https://t.co/BTpwo6ww7W
Dr. John Cush RheumNow ( View Tweet)
ACR 2024 Abstracts are available.
Let the fun begin.....
https://t.co/uNLZBqjEX0
Search by term, title or abstract # here: https://t.co/Du1eN4gA9D
or
Search by sessions and topics here >> https://t.co/R7NH1jeHPj https://t.co/OCoTPr03nG
Links:
Dr. John Cush RheumNow ( View Tweet)
ACR 2024 Abstracts are available.
Let the fun begin.....
https://t.co/uNLZBqjEX0
Search by term, title or abstract # here: https://t.co/Du1eN4gA9D
or
Search by sessions and topics here >> https://t.co/R7NH1jeHPj https://t.co/OCoTPr03nG
Dr. John Cush RheumNow ( View Tweet)
ACR 2024 Abstracts are available.
Let the fun begin.....
https://t.co/uNLZBqjEX0
Search by term, title or abstract # here: https://t.co/Du1eN4gA9D
or
Search by sessions and topics here >> https://t.co/R7NH1jeHPj https://t.co/OCoTPr03nG
Dr. John Cush RheumNow ( View Tweet)
Systemic Sclerosis Insights (9.13.2024)
https://t.co/fRbKdSAqxG https://t.co/PMbYDXPHMd
Dr. John Cush RheumNow ( View Tweet)
Systemic Sclerosis Insights (9.13.2024)
Dr. Jack Cush reviews the news and journal articles from this past week on RheumNow.com.
Read Article
Linger on the Fingers (9.6.2024)
Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow. This week with a focus on fingers and better prescriptive follow through.
https://t.co/c9yvRjE9av https://t.co/mdN37AWHjX
Dr. John Cush RheumNow ( View Tweet)
Claims analysis of two datasets showed TNFi treatment in 1st two years after newly Dx breast cancer (n 2216) had no effect on overall survival (OS); but had signif better breast cancer survival (HR 0.28; 0.08–0.98) vs csDMARD Rx. Pts on GC worse OS (HR 2.18)… https://t.co/Kxk7Sy7ahi https://t.co/PtxRsTifi1
Dr. John Cush RheumNow ( View Tweet)